A Phase 4 interventional study of Rabeprazole and Lansoprazole in Reflux Esophagitis, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-08-13.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by gastroesophageal reflux; deterioration of the protective lining on the inner wall of the lower esophagus); and to evaluate the cure rate of reflux esophagitis on endoscopy (a thin flexible tube with a microscopic camera at the end which is passed down your throat into the esophagus, stomach, and duodenum) after treatment with rabeprazole and lansoprazole.
This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), multi-center (conducted in more than 1 center), randomized (study drug assigned by chance) study in participants with reflux esophagitis. The study will include 4 visits: Visit 1 (Screening period of up to 14 days), Visit 2 (Day 1), Visit 3 (Day 29+3), and Visit 4 (Day 56). After Screening, eligible participants will be analyzed on Visit 2 (Day 1) for symptoms during past week, At visit 3 (Day 29+3) participants will be randomly assigned to 1 of the 2 treatment groups: rabeprazole 20 milligram (mg) or lansoprazole 30 mg group. Participants will receive rabeprazole 20 mg tablet orally once daily for 28 to 56 days or lansoprazole 30 mg capsule orally once daily for 28 to 56 days. A post-study follow-up visit will be conducted only if participant will be affected by any serious adverse event within 30 days after the completion of study drug. Participants will primarily be assessed for the cure rate of reflux esophagitis based on endoscopy of 2 groups. Participants' safety will be monitored throughout the study.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
This study's enrollment of 217 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Browse Esophagitis, Peptic studies →Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
Drug: Rabeprazole
Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
Drug: Lansoprazole
Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
Percentage of Participants Completely Cured of Reflux Esophagitis Evaluated by Endoscopy Based on CYP2C19
Reflux esophagitis evaluated by endoscopy as per LA Classification graded as: A=1 or more mucosal breaks no longer than 5 millimeter (mm) that did not extend between tops of 2 mucosal folds, B=1 or more mucosal breaks more than 5 mm long that did not extend between tops of 2 mucosal folds, C=1 or more mucosal break continuous between the tops of 2 or more mucosal folds but involves less than 75 percent of circumference, D=1 or more mucosal break involving at least 75 percent of circumference. Participants that were not categorized in any of the above mentioned grades (A to D) were considered as cured of reflux esophagitis. Participants were classified as CYP2C19 homozygous extensive, heterozygous extensive and poor metabolizers.
Time frame: Day 57
Change From Baseline in Symptoms of Reflux Esophagitis Evaluated by the Symptom Assessment Questionnaire
Gastroesophageal reflux disease and abdominal GI-related symptoms (heartburn, regurgitation, globus sensation, chronic cough, epigastric pain, non cardiac chest pain, hoarseness, dysphagia, abdominal distension, bloating, post-prandial discomfort, early satiety, nausea, vomiting, belching) experienced by participants were assessed and graded into 4 categories: 0 (Nothing)=No symptom, 1 (Mild)=A little but not uncomfortable, 2 (Moderate)=Present but interfering daily life activities a little, 3 (Severe)=Very uncomfortable, interfering daily life activities or sleeping.
Time frame: Baseline and Day 57
Overall Assessment of Study Medication by Investigator
Investigator's overall assessment of study medication based on the global symptom assessment was measured. The assessment was categorized as: 2=very good, 1=good, 0=as usual, -1=bad and -2=very bad.
Time frame: Day 57
| Milestone | Rabeprazole | Lansoprazole |
|---|---|---|
| Started | 108 | 109 |
| Completed | 91 | 92 |
| Not completed | 17 | 17 |
| Withdrew: Participant's evasion of hospital visit | 5 | 4 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Physician decision | 5 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Participants' non-cooperation | 2 | 3 |
| Withdrew: Other | 2 | 3 |
| Withdrew: Other | 0 | 2 |
Reflux esophagitis evaluated by endoscopy as per LA Classification graded as: A=1 or more mucosal breaks no longer than 5 millimeter (mm) that did not extend between tops of 2 mucosal folds, B=1 or more mucosal breaks more than 5 mm long that did not extend between tops of 2 mucosal folds, C=1 or more mucosal break continuous between the tops of 2 or more mucosal folds but involves less than 75 percent of circumference, D=1 or more mucosal break involving at least 75 percent of circumference. Participants that were not categorized in any of the above mentioned grades (A to D) were considered as cured of reflux esophagitis. Participants were classified as CYP2C19 homozygous extensive, heterozygous extensive and poor metabolizers.
| Percentage of participants | Rabeprazole | Lansoprazole |
|---|---|---|
| Homozygous Extensive Metabolizer (n=42, 35) | 97.37 | 93.94 |
| Heterozygous Extensive Metabolizer (n=30, 38) | 100.00 | 100.00 |
| Poor Metabolizer (n=15, 18) | 93.33 | 100.00 |
Gastroesophageal reflux disease and abdominal GI-related symptoms (heartburn, regurgitation, globus sensation, chronic cough, epigastric pain, non cardiac chest pain, hoarseness, dysphagia, abdominal distension, bloating, post-prandial discomfort, early satiety, nausea, vomiting, belching) experienced by participants were assessed and graded into 4 categories: 0 (Nothing)=No symptom, 1 (Mild)=A little but not uncomfortable, 2 (Moderate)=Present but interfering daily life activities a little, 3 (Severe)=Very uncomfortable, interfering daily life activities or sleeping.
| Units on a scale | Rabeprazole | Lansoprazole |
|---|---|---|
| Baseline: Heartburn (n=87, 91) | 0.61 ± 0.84 | 0.59 ± 0.89 |
| Baseline:Regurgitation (n=87, 91) | 0.98 ± 0.93 | 0.93 ± 0.96 |
| Baseline: Globus sensation (n=87, 91) | 0.55 ± 0.82 | 0.82 ± 0.78 |
| Baseline: Chronic cough (n=87, 91) | 0.34 ± 0.70 | 0.30 ± 0.66 |
| Baseline: Epigastric pain (n=87, 90) | 0.91 ± 1.00 | 0.94 ± 0.95 |
| Baseline: Non cardiac chest pain (n=85, 90) | 0.33 ± 0.71 | 0.26 ± 0.66 |
| Baseline: Hoarseness (n=87, 90) | 0.23 ± 0.54 | 0.22 ± 0.54 |
| Baseline: Dysphagia (n=87, 91) | 0.16 ± 0.50 | 0.22 ± 0.57 |
| Baseline: Abdominal distension (n=87, 91) | 0.61 ± 0.84 | 0.59 ± 0.80 |
| Baseline: Bloating (n=87, 90) | 0.55 ± 0.82 | 0.44 ± 0.75 |
| Baseline: Post-prandial discomfort (n=87, 91) | 0.53 ± 0.78 | 0.55 ± 0.76 |
| Baseline: Early satiety (n=86, 91) | 0.27 ± 0.58 | 0.25 ± 0.55 |
| Baseline: Nausea (n=87, 91) | 0.16 ± 0.48 | 0.13 ± 0.37 |
| Baseline: Vomiting (n=87, 91) | 0.08 ± 0.38 | 0.02 ± 0.15 |
| Baseline: Belching (n=87, 91) | 0.38 ± 0.70 | 0.36 ± 0.62 |
| Change at Day 57: Heartburn (n=87, 91) | -0.55 ± 0.83 | -0.54 ± 0.90 |
| Change at Day 57: Regurgitation (n=87, 91) | -0.89 ± 0.93 | -0.84 ± 0.95 |
| Change at Day 57: Globus sensation (n=87, 91) | -0.31 ± 0.69 | -0.32 ± 0.66 |
| Change at Day 57: Chronic cough (n=87, 91) | -0.22 ± 0.64 | -0.21 ± 0.61 |
| Change at Day 57: Epigastric pain (n=87, 90) | -0.77 ± 0.95 | -0.77 ± 0.92 |
| Change at Day 57:Non cardiac chest pain (n=85, 90) | -0.28 ± 0.65 | -0.20 ± 0.54 |
| Change at Day 57: Hoarseness (n=87, 90) | -0.14 ± 0.51 | -0.17 ± 0.55 |
| Change at Day 57: Dysphagia (n=87, 91) | -0.11 ± 0.44 | -0.14 ± 0.48 |
| Change at Day 57: Abdominal distension (n=87, 91) | -0.38 ± 0.80 | -0.40 ± 0.76 |
| Change at Day 57: Bloating (n=87, 90) | -0.41 ± 0.72 | -0.37 ± 0.69 |
| Change at Day57:Post-prandial discomfort (n=87,91) | -0.45 ± 0.73 | -0.35 ± 0.74 |
| Change at Day 57: Early satiety (n=86, 91) | -0.21 ± 0.49 | -0.16 ± 0.58 |
| Change at Day 57: Nausea (n=87, 91) | -0.16 ± 0.48 | -0.11 ± 0.38 |
| Change at Day 57: Vomiting (n=87, 91) | -0.08 ± 0.38 | -0.02 ± 0.15 |
| Change at Day 57: Belching (n=87, 91) | -0.25 ± 0.70 | -0.29 ± 0.54 |
Investigator's overall assessment of study medication based on the global symptom assessment was measured. The assessment was categorized as: 2=very good, 1=good, 0=as usual, -1=bad and -2=very bad.
| Units on a scale | Rabeprazole | Lansoprazole |
|---|---|---|
| Overall Assessment of Study Medication by Investigator | 1.37 ± 0.71 | 1.43 ± 0.74 |
Collected over Baseline up to Day 57. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rabeprazole | — | 2/108 (1.9%) | 42/108 (38.9%) |
| Lansoprazole | — | 0/109 (0%) | 42/109 (38.5%) |
| Event | Rabeprazole | Lansoprazole |
|---|---|---|
| Diabetes mellitusMetabolism and nutrition disorders | 1/108 | 0/109 |
| Haemorrhoid operationSurgical and medical procedures | 1/108 | 0/109 |
| Event | Rabeprazole | Lansoprazole |
|---|---|---|
| Abdominal distensionGastrointestinal disorders | 19/108 | 18/109 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/108 | 15/109 |
| Abdominal painGastrointestinal disorders | 12/108 | 17/109 |
| Sensation of foreign bodyGeneral disorders | 13/108 | 16/109 |
| DyspepsiaGastrointestinal disorders | 10/108 | 15/109 |
| Abdominal pain upperGastrointestinal disorders | 9/108 | 12/109 |
| Early satietyGeneral disorders | 11/108 | 11/109 |
| DysphagiaGastrointestinal disorders | 10/108 | 10/109 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 9/108 | 9/109 |
| NauseaGastrointestinal disorders | 8/108 | 9/109 |
Baseline characteristics were measured for full analysis set (FAS) population. It included participants who received study medication at least once and had follow-up data that could be used after Baseline among participants who met eligibility criteria. Last observation carried forward (LOCF) was used.
| Age Continuous(Years) | Rabeprazole | Lansoprazole | Total |
|---|---|---|---|
| Mean | 49.70 ± 11.72 | 49.74 ± 12.65 | 49.72 ± 12.17 |
| Sex: Female, Male(Participants) | Rabeprazole | Lansoprazole | Total |
|---|---|---|---|
| Female | 12 | 22 | 34 |
| Male | 75 | 69 | 144 |
No study locations are listed for this record.
The record gives a start of May 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rabeprazole